![]() |
市場調査レポート
商品コード
1614785
ZYNRELEF市場:市場規模、予測、新たな洞察-2032年ZYNRELEF Market Size, Forecast, and Market Insight - 2032 |
||||||
カスタマイズ可能
適宜更新あり
|
ZYNRELEF市場:市場規模、予測、新たな洞察-2032年 |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
ZYNRELEF(旧名HTX-011)(ブピバカイン、メロキシカム)は、局所アミド麻酔薬であるブピバカインと非ステロイド性抗炎症薬(NSAID)であるメロキシカムを含有し、成人において、外反母趾切除術、鼠径ヘルニア開放術、人工膝関節全置換術の術後72時間までの軟部組織または関節周囲への注入による術後鎮痛を適応としています。この薬剤は、最初で唯一の徐放性二重作用性局所麻酔薬(DALA)であり、針を使用しない1回の塗布で72時間の術後鎮痛をもたらします。ブピバカインとメロキシカムの安定した送達のために、Heron独自の制御拡散Biochronomerポリマーで製剤化されています。
今後数年間で、世界中の広範な調査と医療費の増加により、術後痛の市場シナリオは変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ZYNRELEFの優位性に影響を与える可能性のある機会を模索しています。術後疼痛を対象とする他の新興製品は、ZYNRELEFと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国におけるZYNRELEF市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"ZYNRELEF Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ZYNRELEF for Postoperative pain in the seven major markets. A detailed picture of the ZYNRELEF for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZYNRELEF for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNRELEF market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.
ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) contains bupivacaine, a local amide anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 h after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. It is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 h of postoperative pain relief via a single needle-free application. It is formulated in Heron's proprietary controlled-diffusion Biochronomer polymer for consistently regulated delivery of bupivacaine and meloxicam.
Dosage and administration
The recommended dose of ZYNRELEF is as follows:
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ZYNRELEF Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ZYNRELEF for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of ZYNRELEF for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.